'Moderna Strikes Deal To Develop mRNA Drugs In China' - CNBC
Portfolio Pulse from Benzinga Newsdesk
Moderna has signed a deal with Chinese officials to research, develop, and manufacture mRNA medicines in China. The deal, which could be worth around $1 billion, is Moderna's first agreement with China and the first to involve developing mRNA medicines overall, not just Covid shots. The drugs developed will be exclusively for the Chinese people and will not be exported. This comes despite rising tensions between the U.S. and China.
July 05, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's deal with China to develop mRNA medicines could potentially boost the company's revenues and expand its global footprint. However, the geopolitical tensions between the U.S. and China could pose risks.
The deal with China opens a new market for Moderna, potentially boosting its revenues and expanding its global footprint. However, the ongoing geopolitical tensions between the U.S. and China could pose risks to the deal and Moderna's operations in China.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100